Abbott Laboratories (ABT) News & EventsABTAbbott Laboratories

Abbott Announces Beta-CORRECT Data, WGS Test Achieves 30% Improvement in Colorectal Cancer Recurrence Sensitivity

Abbott announced new Beta-CORRECT data presented at the European Society for Medical Oncology, or ESMO, Congress showing that the whole-genome sequencing, or WGS,-based Oncodetect molecular residual disease, or MRD, test achieved a 30% absolute improvement in sensitivity for colorectal cancer recurrence within two years of surgery, compared with the whole-exome sequencing, or WES, Oncodetect test, using a single post-surgery blood draw. A single blood test taken approximately one month after surgery using the WGS test achieved 72.2% sensitivity for recurrence within two years, compared with 42.2% for the WES test, a 30-percent absolute improvement. Among 157 patients tested post-surgery with both tests, the WGS test detected ctDNA in all 29 patients in whom the WES test identified, plus 15 additional patients. All additional detections were at levels below 20 parts per million, including 14 that were below 10 ppm. Strong prognostic value: Patients with detectable ctDNA after surgery had a 10.6-fold higher risk of recurrence than ctDNA-negative patients. Two-year disease-free survival rates were 36.2% versus 92.3%, respectively. Patients with detectable post-surgical ctDNA had approximately 31-fold higher recurrence risk compared to those who were ctDNA negative. Only 2.8% of stage II patients with undetectable ctDNA experienced recurrence within two years. About the Oncodetect(R) test

Flyte Aviation Subsidiary Releases LockeT Device Clinical Study

Flyte Aviation's wholly owned subsidiary Catheter Precision announced the first published comparative study evaluating its LockeT suture retention device against a traditional internal vascular closure device, or VCD, following large bore venous access. The 172-patient peer-reviewed study was published in The Journal of Interventional Cardiology. The clinical data demonstrated the superior safety and efficacy of the LockeT device compared to Perclose, an internal VCD manufactured and sold by Abbott (ABT). Key findings from the study include: fewer complications: LockeT reduced cumulative access-site complications to just 1.2% vs. 9.3% with Perclose; zero device failures: the LockeT device achieved a 0.0% failure rate, outperforming the VCD's 4.7% failure rate; equivalent efficiency: both methods delivered similar results for time to hemostasis and rates of same-day patient discharge.

Nasdaq Rises on SpaceX Earnings Report

The major averages closed broadly higher, led by the Nasdaq following upbeat results from SpaceX and Super Micro Computer. In addition to the space technology company reporting its first profit as a public company, Elon Musk said a merger with Tesla would be "a good idea," but one that needs to be studied by special committees formed by each of the companies' boards.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:SpaceXreported better-than-expected Q3 results, with the company noting it has 13.6M Starlink consumer subscribers and 11,100 satellites in orbitMeanwhile, Elon Musk said that SpaceX and Teslahave formed committees to consider a possible mergerNetflixreported upbeat Q3 results but provided a lower-than-expected outlook for Q4Abbottreported better-than-expected Q3 earnings and revenue and announced it will separate its global Nutrition business into an independent companyNvidiaintroduced DSX POD, a reference design for complete Vera Rubin AI factories built by partners inside modular containers2. WALL STREET CALLS:Netflixcut to Hold at Needham amid decelerating revenue growthNorthrop Grummanupgraded to Outperform at BairdChipotledowngraded to Hold at TD CowenZoom Communicationsupgraded to Outperform at OppenheimerBarclays downgraded Cirrus Logicto Underweight on Applesupply chain concerns3. AROUND THE WEB:Blackstoneand a unit of Apollo Globalare in discussion with the National Football League to join the league's list of approved private equity firms that can acquire minority interests in its franchises, Bloomberg reportsU.S. Senators Richard Blumenthal and Josh Hawley have sent a letter to GoogleCEO Sundar Pichai seeking answers about what the company knows about its AI tools' impact on children's mental health and educational development, WSJ saysMeta'sMuse AI companion surpassed 10M U.S. downloads within its first 40 days, ranking among just a dozen mobile apps to reach that milestone, TechCrunch saysAkzo Nobelis in early talks to sell its European vehicle refinishing business to secure antitrust approval for its planned $19B merger with Axalta, WSJ reportseBayplans to cut about 9% of its workforce to simplify operations and redirect resources toward faster-growing areas, following 6% layoffs in February, Reuters says4. MOVERS:Super Microgained after the company raised its Q1 revenue viewApplied Digitalincreased after Roth Capital reinstated coverage of the stock with a Buy ratingRoivantwas higher in New York after announcing its CLARITY-1 and CLARITY-2 trials met its primary endpointsAT&Twas lower after reporting Q3 results and raising its outlook for FY26Pegasystemsfell after reporting Q3 results5. EARNINGS/GUIDANCE:Thermo Fisherreported Q3 results and raised its guidance for FY26, with CEO Marc Casper calling it "another excellent quarter"Elevance Healthreported Q3 results and raised its outlook for FY26Danaherreported Q3 results, provided guidance for Q4, and increased its outlook for FY26UDRreported preliminary Q3 resultsWinnebagoreported Q4 results and provided guidance for FY27INDEXES:The Dow rose 360.21, or 0.69%, to 52,856.09, the Nasdaq gained 278.04, or 1.05%, to 26,702.86, and the S&P 500 advanced 44.60, or 0.58%, to 7,757.17.